{"entity":{"id":"lymphoma-ev-genetic-subtype-directed-first-line","kind":"idea","name":"Assign first-line treatment in diffuse large B-cell lymphoma by genetic subtype, not by a three-antibody stain","aka":["LymphGen-directed first-line therapy","Genetic subtype-directed treatment in diffuse large B-cell lymphoma"],"tldr":"Three genetic classifications of the commonest aggressive lymphoma exist and none of them yet decides anyone's treatment. The trial that would change that has not been run.","summary":"The obstacles are concrete rather than conceptual. Comprehensive classification needs copy number and structural variants as well as mutations, which routine panels do not generate; a turnaround time short enough to decide first-line treatment in an aggressive lymphoma means days, not weeks; and a proportion of tumours remain unclassified by design. Any trial has to report that proportion honestly, because a classifier that works on two-thirds of patients is a different clinical proposition from one that works on all of them. The training cohorts were also largely of European ancestry, which is a validation gap rather than a flaw.","asOf":"2026-10-01","links":[],"tags":["lymphoma-evidence"],"related":["lymphoma-roadmap"],"cancers":["dlbcl","non-hodgkin-lymphoma"],"sections":["diagnostics","targeted-therapy"],"technologies":["wes-wgs","ngs"],"targets":["myd88","cd79b","bcl2","btk","ezh2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cell-of-origin"],"trials":[],"people":[],"bottlenecks":["b-biomarker-validation","b-trial-design","b-translational-valley"],"keyPapers":["paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Assigning first-line treatment in diffuse large B-cell lymphoma by LymphGen genetic subtype improves progression-free survival over assigning it by cell-of-origin immunohistochemistry or by giving everyone R-CHOP.","rationale":"Schmitz showed that two of the four genetic subtypes, MCD and BN2, depend on chronic active B-cell receptor signalling, which Bruton tyrosine kinase inhibitors block, and that outcomes differ sharply between subtypes after immunochemotherapy. PHOENIX, which selected by the non-germinal-centre immunohistochemistry phenotype rather than by genetics, failed overall while producing long remissions in a subgroup. Wright's LymphGen tool makes per-patient classification possible with a probability attached. The pieces exist; nobody has put them in a randomised trial of first-line treatment.","test":"A randomised first-line trial in diffuse large B-cell lymphoma with comprehensive genomic profiling at diagnosis, assigning treatment by LymphGen subtype in the experimental arm (a Bruton tyrosine kinase inhibitor or a BCL2 inhibitor added to R-CHOP for the subtypes predicted to benefit, standard R-CHOP for the rest) against R-CHOP for everyone, powered on progression-free survival, with the proportion of tumours successfully classified reported as a co-primary feasibility endpoint.","maturity":"preclinical-evidence","actor":"research","cost":"large","horizonYears":8},"route":"/ideas/lymphoma-ev-genetic-subtype-directed-first-line/","neighbours":{"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"term":[{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"},{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"}],"paper":[{"id":"paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","kind":"paper","name":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","route":"/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/"},{"id":"paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","kind":"paper","name":"Genetics and pathogenesis of diffuse large B-cell lymphoma","route":"/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/"},{"id":"paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","kind":"paper","name":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","route":"/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"}]}}